Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | F12 | P00748 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29986248 | 1.00 | PLAU (0.50) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL31122674 | 0.98 | PLAU (0.48) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL3250398 | 0.96 | PLAU (0.50) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL18154032 | 0.94 | PLAU (0.48) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL10477025 | 0.93 | ACHE (0.53) | PLAUCYP2A6F12NCF1NOS3 | |
| Bromide SCHEMBL18154039 | 0.92 | PLAU (0.47) | PLAUCYP2A6F12NCF1NOS3 | |
| Hydrochloric Acid SCHEMBL11152119 | 0.92 | PLAU (0.47) | PLAUCYP2A6F12NCF1NOS3 | |
| Hydrochloric Acid SCHEMBL9852596 | 0.91 | ACHE (0.52) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL282759 | 0.89 | PLAU (0.44) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL4067893 | 0.89 | CYP2A6 (0.48) | PLAUCYP2A6F12NCF1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1998775-B1 | BIS1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR USES AS PHARMACEUTICALS | UNIV LIEGE (BE) | 2010-05-19 | — | — | EP | disclosed |
| US-20090093517-A1 | BIS1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR USES AS PHARMACEUTICALS | UNIVERSITE DE LIEGE (BE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093517-A1 | BIS1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR USES AS PHARMACEUTICALS | KCNQ2, KCNQ1, KCNQ3 | PLAU 3845/4885CYP2A6 654/4885F12 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.